Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Three high-impact sepsis studies stood out: a target trial emulation showed that early appropriate antibiotics substantially reduce mortality in hospital-acquired Gram-negative bloodstream infections; mechanistic work identified P2Y12 signaling in renal proximal tubules as a modifiable driver of sepsis-associated AKI with ticagrelor as a repurposing candidate; and endothelial barrier failure was mechanistically linked to a PAFAH2–ECHS1–protein crotonylation axis.
Research Themes
- Timely appropriate antimicrobial therapy in sepsis
- Endothelial and renal mechanisms driving organ injury
- Drug repurposing and novel molecular targets
Selected Articles
1. Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections.
In a 22-center prospective cohort emulating a target trial (n=680), early appropriate antimicrobial therapy for hospital-acquired monobacterial Gram-negative bloodstream infections reduced 14-day mortality (aHR 0.41) and 28-day mortality (aHR 0.66) versus late therapy. Benefits persisted in carbapenem-resistant infections and across sensitivity analyses.
Impact: Provides robust causal-inference evidence that timing of appropriate therapy materially affects mortality in a high-risk population, informing stewardship and time-to-therapy targets.
Clinical Implications: Prioritize rapid identification and initiation of appropriate antibiotics for hospital-acquired Gram-negative bloodstream infections, especially in carbapenem-resistant cases; implement workflows (rapid diagnostics, stewardship protocols) to minimize delays.
Key Findings
- Among 680 adults, 14-day mortality was 14.7% with EAAT vs 42.9% with LAAT; aHR 0.41 (95% CI 0.28–0.61).
- 28-day mortality was 26.1% with EAAT vs 49.5% with LAAT; aHR 0.66 (95% CI 0.50–0.86).
- In carbapenem-resistant Gram-negative infections, EAAT reduced 14-day mortality (aHR 0.36) and 28-day mortality (aHR 0.60).
- Results were consistent across prespecified and post hoc sensitivity analyses using inverse probability weighting and time-dependent exposure.
Methodological Strengths
- Target trial emulation with inverse probability weighting and time-dependent treatment modeling.
- Multi-centre prospective cohort across 22 hospitals with prespecified and post hoc sensitivity analyses.
Limitations
- Observational emulation cannot eliminate residual confounding despite advanced methods.
- Generalizability limited to participating centers; potential misclassification of timing/appropriateness.
Future Directions: Test implementation strategies (rapid diagnostics, stewardship bundles) in pragmatic trials to reduce time-to-appropriate therapy; explore causal pathways and patient subgroups benefiting most.
BACKGROUND: Delays in appropriate antimicrobial therapy can increase the risk of all-cause mortality (ACM) in hospital-acquired bloodstream infections (HA-BSIs) caused by Gram-negative bacteria (GNB). We aimed to evaluate the effectiveness of early appropriate antimicrobial therapy (EAAT) compared with late appropriate antimicrobial therapy (LAAT) in this population. METHODS: This study used data from a multi-centre, prospective cohort including adult patients with HA-BSI caused by GNB across 22 Turkish hospitals. A hypothetical target trial allocating participants with HA-BSI caused by monobacterial GNB to either EAAT or LAAT was emulated using the weighting approach. The primary outcome was 14 day ACM; 28 day ACM was a secondary outcome. Cox proportional hazards models with inverse probability weighting were applied to account for confounding, with antibiotic treatment incorporated as a time-dependent variable. RESULTS: Among 680 patients, 14 day ACM occurred in 14.7% (40/272) of the EAAT group and 42.9% (175/408) of the LAAT group. EAAT was associated with a lower risk of 14 day ACM [adjusted hazard ratio (aHR) = 0.41; 95% CI: 0.28-0.61). Similarly, 26.1% (71/272) of the patients treated with EAAT and 49.5% (202/408) of those receiving LAAT died during 28 day follow-up (aHR = 0.66; 95% CI: 0.50-0.86). In the carbapenem-resistant GNB subset, EAAT reduced the hazard of 14 day ACM (aHR = 0.36; 95% CI: 0.21-0.60) and 28 day ACM (aHR = 0.60; 95% CI: 0.44-0.84). All prespecified and post hoc analyses consistently supported these findings. CONCLUSIONS: EAAT was associated with a survival benefit in individuals with HA-BSI due to GNB. Although these findings support early initiation of appropriate therapy, residual confounding cannot be excluded.
2. Ticagrelor protects sepsis-associated acute kidney injury by modulating renal gluconeogenesis and inflammation through the P2Y12 receptor in proximal tubule cells.
P2Y12 is upregulated in proximal tubules during SA-AKI, driving Gi-dependent suppression of cAMP-PKA, heightened cytokine production, and impaired gluconeogenesis. Genetic ablation or ticagrelor-mediated inhibition of P2Y12 restores signaling and metabolism, reduces inflammation, and protects kidneys, positioning P2Y12 blockade as a repurposable therapeutic strategy.
Impact: Reveals a druggable renal pathway linking inflammation and metabolism in SA-AKI and proposes repurposing a widely used antiplatelet agent with established safety data.
Clinical Implications: Supports exploration of ticagrelor as an adjunctive therapy for SA-AKI, with careful evaluation of bleeding risk and dosing; suggests P2Y12-related biomarkers for patient selection and monitoring.
Key Findings
- P2Y12 expression markedly increases in proximal tubule cells after LPS challenge and promotes Gi signaling that suppresses cAMP-PKA.
- P2Y12 activation elevates proinflammatory cytokines and disrupts renal gluconeogenesis; single-molecule imaging visualizes P2Y12–Gi interaction.
- Genetic deletion or ticagrelor inhibition of P2Y12 restores cAMP-PKA, reduces inflammation, preserves gluconeogenic function, and mitigates kidney injury in vivo.
Methodological Strengths
- Integrated mechanistic approach: genetic models, pharmacologic inhibition, and single-molecule imaging.
- In vivo validation of renal protection alongside in vitro mechanistic dissection.
Limitations
- Preclinical models; absence of human clinical data or randomized testing.
- Potential systemic effects of P2Y12 inhibition (e.g., platelet function, bleeding) not addressed in depth.
Future Directions: Early-phase clinical trials to assess safety, dosing, and efficacy of ticagrelor in SA-AKI; development of biomarkers to identify P2Y12-driven phenotypes.
Sepsis-associated acute kidney injury (SA-AKI) is characterized by tubular inflammation and impaired metabolism, yet effective treatments remain lacking. Here, we identify the purinergic receptor P2Y12 as a key regulator of these pathological processes in renal proximal tubule cells. P2Y12 expression is markedly upregulated after lipopolysaccharide challenge. Mechanistically, P2Y12 activation promotes Gi signaling, suppresses the cAMP-PKA pathway, increases proinflammatory cytokine production, and disrupts gluconeogenesis. Using single-molecule imaging, we directly visualize the interaction between P2Y12 and Gi proteins in tubular cells. Genetic deletion of P2Y12 or pharmacological inhibition with ticagrelor, a clinically approved P2Y12 antagonist, restores cAMP-PKA signaling, attenuates inflammation, and preserves gluconeogenic function, ultimately mitigating kidney injury. These findings uncover a previously unrecognized role of P2Y12 in SA-AKI and highlight the therapeutic potential of targeting P2Y12 signaling with existing drugs. Our study provides new mechanistic insight and suggests a promising strategy for repurposing ticagrelor in the treatment of SA-AKI.
3. PAFAH2 deficiency drives sepsis-induced vascular leakage by promoting ECHS1-mediated suppression of protein crotonylation and mitochondrial dysfunction.
In sepsis models, endothelial PAFAH2 is downregulated, driving ECHS1 upregulation that suppresses protein crotonylation, disrupts mitochondrial function, and increases endothelial apoptosis, culminating in vascular leak and lung injury. Restoring PAFAH2 or modulating ECHS1 reverses these effects, nominating crotonylation control as a barrier-protective strategy.
Impact: Uncovers a previously unappreciated PAFAH2–ECHS1–crotonylation axis linking lipid mediator metabolism, mitochondrial health, and endothelial barrier failure in sepsis.
Clinical Implications: Suggests endothelial-targeted interventions—enhancing PAFAH2 activity, inhibiting ECHS1, or restoring protein crotonylation—as potential strategies to reduce vascular leak in sepsis, warranting translational development.
Key Findings
- Septic rats displayed lung injury and increased vascular leak associated with mitochondrial dysfunction and reduced survival.
- Endothelial PAFAH2 was downregulated after sepsis, driving ECHS1 upregulation that suppressed protein crotonylation and impaired mitochondrial function, increasing apoptosis.
- PAFAH2 overexpression reduced vascular leakage by downregulating ECHS1 and enhancing crotonylation; modulation of PAFAH2/ECHS1 mitigated adverse effects.
Methodological Strengths
- Combined in vivo CLP rat model and in vitro LPS-stimulated endothelial cell experiments.
- Mechanistic gain- and loss-of-function studies linking crotonylation and mitochondrial function to barrier integrity.
Limitations
- Preclinical models limit direct clinical generalizability; human endothelial validation is lacking.
- Specificity of crotonylation effects and off-target consequences of modulating PAFAH2/ECHS1 require further study.
Future Directions: Validate the PAFAH2–ECHS1–crotonylation axis in human tissues, develop pharmacologic modulators, and test endothelial-targeted therapies in translational sepsis models.
BACKGROUND: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The vascular endothelial cells (VECs) play a pivotal role in the progression of sepsis-induced vascular leakage. While therapeutic strategies targeting pathogen elimination and inflammation exist, direct interventions on the endothelial barrier are limited. The mechanisms of endothelial damage related to mitochondrial dysfunction during sepsis require further elucidation. METHODS: The study utilized a cecal ligation and puncture (CLP) rat model of sepsis and lipopolysaccharide (LPS)-stimulated VECs to investigate vascular leakage mechanisms. These models were utilized to investigate the changes in vascular permeability, mitochondrial function and protein crotonylation in VECs, aiming to identify potential therapeutic targets for sepsis. RESULTS: In septic rats, significant lung injury and increased vascular leakage were observed, linked to mitochondrial dysfunction and decreased survival rates. A marked downregulation of Platelet Activating Factor Acetylhydrolase 2 (PAFAH2) in VECs was identified post-sepsis, causing an upregulation of Enoyl-CoA Hydratase, Short Chain 1 (ECHS1), which inhibited crotonylation and compromised mitochondrial function, leading to increased apoptosis of VECs. Restoration experiments showed that modulating PAFAH2 and ECHS1 levels could mitigate these adverse effects. PAFAH2 overexpression alleviated sepsis-induced vascular leakage by downregulating ECHS1 and enhancing crotonylation. CONCLUSIONS: The study identifies the PAFAH2-ECHS1 pathway as a critical axis in sepsis-induced vascular leakage, influencing mitochondrial function and crotonylation, which leads to endothelial apoptosis. These insights could guide the development of new therapies targeting the endothelial barrier for treating sepsis.